


Under the Paper Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



TRANSMITTAL FORM

(To be used for all correspondence after initial filing)

Application Number		10/805,788
Filing Date		Mar 22, 2004
First Named Inventor		Quay, Steven C.
Art Unit		1654
Examiner Name		Thomas Sweeney Heard
Total Number of Pages in This Submission	4	Attorney Docket Number 03-04US

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement - Substitute page 2 only <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance communication to (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Form SB08a - page two with correction in red
Remarks On August 19, 2005, we filed a three-page IDS. We noted a typographical error on the first line of the "U.S. Patent Documents" section. The Takeda Chemical Industries (corrected from Coflexip) U.S. Patent Number has been corrected from 5,428,706 to the correct patent number of 5,482,706. Please switch out the prior page two for this new page two. Thank you.		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Nastech Pharmaceutical Company Inc.		
Signature			
Printed name	Peter J. Knudsen		
Date	January 18, 2007	Reg. No.	40682

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Signature			
Typed or printed name		Date	January 18, 2007

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

In you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Quay et al.

Serial No.: 10/805,788

Filed: 3/22/2004

Title: NASAL CALCITONIN
FORMULATIONS CONTAINING
CHLOROBUTANOL

Assignee: Natestch Pharmaceutical Company
Inc. by Reel 014824 /Frame 0710

Group Art Unit: 1654

Examiner: Thomas Sweeney Heard

Attorney Docket No.: 03-04US

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUBSTITUTE INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants submit herewith a substitute Form PTO SB08a-Information Disclosure Statement by Applicant-page two only, to correct a typographical error on a U.S. patent number and name of Applicant cited.

It is requested that the information disclosed herein be made of record in this application.

Respectfully submitted,

I hereby certify that this Correspondence is being deposited with the United States Postal service with sufficient postage for first class mail in an envelope address to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or the correspondence is being facsimile transmitted to the USPTO, on the date indicated below.

Date of Deposit: 01/18/2007

Typed Name: Kerry King

Signature: Kerry King

Peter J. Knudsen
Attorney for Applicants
Natestch Pharmaceutical Company Inc.
3830 Monte Villa Parkway
Bothell, WA 98021-7266
(425) 908-3643 phone
(425) 908-3653 fax
pknudsen@natestch.com
Reg. No.: 40,682



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/805,788	
				Filing Date	3/22/2004	
				First Named Inventor	Quay et al.	
				Art Unit	1614	
				Examiner Name		
Sheet	2	of	3	Attorney Docket Number	03-04US	
U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Number - Kind ² Code ² (if known)				
		US-5,428,700	Issued 6-27-1995	Coflexip	Takeda Chemical Industries, Ltd.	
		US-5,482,931	Issued 01-09-1996	Ferring AB		
		US-5,503,827	Issued 04-02-1996	Boehringer Mannheim GmbH		
		US-5,508,260	Issued 04-16-1996	Amylin Pharmaceuticals, Inc.		
		US-5,514,365	Issued 05-07-1996	Schiapparelli Salute S.P.A.		
		US-5,527,771	Issued 06-18-1996	Amylin Pharmaceuticals, Inc.		
		US-5,554,378	Issued 09-10-1996	Takeda Chemical Industries,		
		US-5,565,423	Issued 10-15-1996	Hoechst Aktiengesellschaft		
		US-5,574,006	Issued 11-12-1996	Dott Research Laboratory		
		US-5,576,016	Issued 11-19-1996	Pharmos Corporation		
		US-5,578,324	Issued 11-26-1996	Teijin Limited		
		US-5,603,943	Issued 02-18-1997	Dott Research Laboratory		
		US-5,654,000	Issued 08-05-1997	Poli Industria Chimica S.p.A.		
		US-5,681,811	Issued 10-28-1997	Protein Delivery, Inc.		
		US-5,693,608	Issued 12-02-1997	Bechgaard International Research and Development		
		US-5,719,122	Issued 02-17-1998	SmithKline Beecham Farmaceutici S.p.A.		
		US-5,725,852	Issued 03-10-1998	Takeda Chemical Industries,		
		US-5,725,871	Issued 03-10-1998	Danbiosyst UK Limited		
		US-5,733,569	Issued 03-31-1998	Novartis Corporation		
FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	† ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
		GB 2 177 914 A	02-04-1987	Chugai Seiyaku Kabushiki Kaisha		
		EP 0 358 234 A2	03-14-1990	Rorer International (Overseas) Inc.		
		EP 0 371 010 A1	05-30-1990	Yamanouchi Pharmaceutical Co. Ltd.		
		EP 0 418 697 A1	03-27-1991	Esseit s.a.s. Laboratorio Chimico Farmaco Biologico Di A. Ievoli & C.		
		EP 0 471 618 A1	08-12-1991	Toyo Jozo Co., Ltd.		
		EP 0 489 217 A1	06-10-1992	DR. A Tosi Farmaceutici S.R.L.		
Examiner Signature				Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known		
				Application Number	10/805,788	
				Filing Date	3/22/2004	
				First Named Inventor	Quay et al.	
				Art Unit	1654	
				Examiner Name	Thomas Sweeney Heard	
Sheet	2	of	3	Attorney Docket Number	03-04US	
U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Number - Kind Code ² (if known)				
		US-5,482,706	Issued 6-27-1995	Takeda Chemical Industries, Ltd.		
		US-5,482,931	Issued 01-09-1996	Ferring AB		
		US-5,503,827	Issued 04-02-1996	Boehringer Mannheim GmbH		
		US-5,508,260	Issued 04-16-1996	Amylin Pharmaceuticals, Inc.		
		US-5,514,365	Issued 05-07-1996	Schiapparelli Salute S.P.A.		
		US-5,527,771	Issued 06-18-1996	Amylin Pharmaceuticals, Inc.		
		US-5,554,378	Issued 09-10-1996	Takeda Chemical Industries, Ltd.		
		US-5,565,423	Issued 10-15-1996	Hoechst Aktiengesellschaft		
		US-5,574,006	Issued 11-12-1996	Dott Research Laboratory		
		US-5,576,016	Issued 11-19-1996	Pharmos Corporation		
		US-5,578,324	Issued 11-26-1996	Teijin Limited		
		US-5,603,943	Issued 02-18-1997	Dott Research Laboratory		
		US-5,654,000	Issued 08-05-1997	Poli Industria Chimica S.p.A.		
		US-5,681,811	Issued 10-28-1997	Protein Delivery, Inc.		
		US-5,693,608	Issued 12-02-1997	Bechgaard International Research and Development A/S		
		US-5,719,122	Issued 02-17-1998	SmithKline Beecham Farmaceutici S.p.A.		
		US-5,725,852	Issued 03-10-1998	Takeda Chemical Industries, Ltd.		
		US-5,725,871	Issued 03-10-1998	Danbiosyst UK Limited		
		US-5,733,569	Issued 03-31-1998	Novartis Corporation		
FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	† ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
		GB 2 177 914 A	02-04-1987	Chugai Seiyaku Kabushiki Kaisha		
		EP 0 358 234 A2	03-14-1990	Rorer International (Overseas) Inc.		
		EP 0 371 010 A1	05-30-1990	Yamanouchi Pharmaceutical Co. Ltd.		
		EP 0 418 697 A1	03-27-1991	Esseit s.a.s. Laboratorio Chimico Farmaco Biologico Di A. Ievoli & C.		
		EP 0 471 618 A1	08-12-1991	Toyo Jozo Co., Ltd.		
		EP 0 489 217 A1	06-10-1992	DR. A Tosi Farmaceutici S.R.L.		

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



This return receipt postcard acknowledges receipt by the U.S.
Patent Office of the following: U.S. Utility patent
Application Serial No. 10/805,788:
Title: NASAL CALCITONIN FORMULATIONS
CONTAINING CHLOROBUTANOL
Inventors: Steven C. Quay, *et. al.*
Mailed to the Commissioner for Patents: 3/22/2004

 X Substitute Information Disclosure Statement
 X PTO Form SB08a – substitute page 2, plus
copy of original with correction in red
 X Transmittal Form

Attorney Docket No.: 03-04US, Project 0130